Ganju and colleagues concluded, These results provide the first large-scale evidence supporting GLP-1RAs as a safe and potentially beneficial adjunct in Crohns disease management. They went on to note that prospective studies and guideline development are urgently needed to define their role in integrated IBD and metabolic care.
The years of fad crash diets, weight fluctuations, restriction, and endless cardio took a toll
Walking is the baseline, 8,000 to 10,000 steps daily supports overall metabolic health without creating excessive caloric demand that makes eating enough protein even harder
Here, we describe the design of the phase 3 evoke and evoke+ trials, the first trials to investigate the efficacy, safety, tolerability, and potential disease-modifying effect of oral semaglutide up to 14 mg versus placebo in participants with early-stage symptomatic AD (MCI or mild dementia)
Semaglutide is a GLP-1 receptor agonist that helps regulate appetite, blood sugar, and digestion
Manufacturer-supported pharmacy fulfillment